BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32113998)

  • 1. Recent insight into the role of FBXW7 as a tumor suppressor.
    Yumimoto K; Nakayama KI
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FBXW7: a critical tumor suppressor of human cancers.
    Yeh CH; Bellon M; Nicot C
    Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of FBXW7 in Gynecologic Malignancies.
    Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
    Cells; 2023 May; 12(10):. PubMed ID: 37408248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of FBXW7 loss of function in human cancers.
    Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
    Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Fbxw7/hCdc4 tumor suppressor in human cancer.
    Tan Y; Sangfelt O; Spruck C
    Cancer Lett; 2008 Nov; 271(1):1-12. PubMed ID: 18541364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
    Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
    Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
    Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
    Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
    Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
    Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
    Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
    Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
    Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
    Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
    Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
    Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Highs and Lows of FBXW7: New Insights into Substrate Affinity in Disease and Development.
    de la Cova CC
    Cells; 2023 Aug; 12(17):. PubMed ID: 37681873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tumor Suppressor FBW7 and the Vitamin D Receptor Are Mutual Cofactors in Protein Turnover and Transcriptional Regulation.
    Salehi-Tabar R; Memari B; Wong H; Dimitrov V; Rochel N; White JH
    Mol Cancer Res; 2019 Mar; 17(3):709-719. PubMed ID: 30606768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver.
    Onoyama I; Suzuki A; Matsumoto A; Tomita K; Katagiri H; Oike Y; Nakayama K; Nakayama KI
    J Clin Invest; 2011 Jan; 121(1):342-54. PubMed ID: 21123947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
    Urick ME; Bell DW
    Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc.
    Zhong L; Zhang Y; Li M; Song Y; Liu D; Yang X; Yang D; Qu H; Lai L; Wang Q; Chen Z
    Aging (Albany NY); 2020 Dec; 12(23):24394-24423. PubMed ID: 33260160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
    Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
    J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
    Babaei-Jadidi R; Li N; Saadeddin A; Spencer-Dene B; Jandke A; Muhammad B; Ibrahim EE; Muraleedharan R; Abuzinadah M; Davis H; Lewis A; Watson S; Behrens A; Tomlinson I; Nateri AS
    J Exp Med; 2011 Feb; 208(2):295-312. PubMed ID: 21282377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.